Exploring Biomarkers in Cancer Treatment
Cambridge, Mass. – Seres Therapeutics, Inc. (Nasdaq: MCRB) is at the forefront of innovation in live biotherapeutics. The company has announced that it will share significant exploratory biomarker data from its SER-155 Phase 1b study at a notable annual meeting hosted by the American Society of Clinical Oncology (ASCO). This key presentation will occur between May 30 and June 3.
Recent Findings on SER-155
The latest data highlights improvements in intestinal epithelial barrier integrity and regulates systemic inflammatory responses. These findings align with SER-155’s goal to mitigate risks linked to bacterial translocation and bloodstream infections (BSIs). Previous results from the Phase 1b study showcased a remarkable 77% relative risk reduction in BSIs, underscoring the therapeutic promise of SER-155.
The Potential of SER-155
This new presentation at ASCO sheds light on how SER-155 may facilitate immune reconstitution in patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Researchers noted increased levels of the homeostatic cytokine IL-7 post-treatment, a crucial factor in promoting T-cell expansion in peripheral blood. Enhanced levels of CD4+ T cells were documented, suggesting SER-155’s significant role in immune recovery.
Comments from Experts
Dr. Marcel van den Brink, an esteemed physician and researcher, expressed optimism about the results. He emphasized the importance of effective immune recovery after allo-HSCT due to the patients' susceptibility to severe infections. According to him, the rise in IL-7 levels and CD4+ T-cell populations associated with SER-155 could provide a vital boost to a patient’s immune defense system, promoting better clinical outcomes.
Future Developments for SER-155
Looking ahead, Seres Therapeutics plans to submit a protocol for a Phase 2 trial of SER-155 in allo-HSCT to regulatory authorities shortly, while actively pursuing partnerships to bolster further clinical development.
Presentation Details
Key details regarding the presentation include:
- Abstract Number: 6554
- Title: Exploratory analyses of immune reconstitution biomarkers from a Phase 1b study of SER-155
- Poster Board #: 170
- Date and Time: June 1, 2025, 9:00 AM - 12:00 PM CT
- Presenter: Dr. Emily Walsh, Director of Research Technologies at Seres Therapeutics
About SER-155
SER-155 is an experimental oral live biotherapeutic product specifically designed to combat gastrointestinal pathogens and promote immune balance. This innovative approach aims to avert bloodstream infections, particularly those involving antibiotic-resistant organisms, enhancing the quality of treatment for patients undergoing allo-HSCT.
Clinical Study Outcomes
In the Phase 1b study, SER-155 demonstrated a significant reduction in BSIs and lessened the need for systemic antibiotics, highlighting its potential as a transformative treatment option. With Breakthrough Therapy designation from federal authorities, SER-155 paves the way for crucial advancements in patient care.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is dedicated to revolutionizing treatment strategies for individuals in medically vulnerable populations with its novel live biotherapeutics. The company successfully developed VOWST™, which became the first FDA-approved oral microbiome therapeutic, marking a pivotal moment in microbiome therapy.
The company is focused on harnessing the potential of SER-155 to address various health challenges, extending its research to multiple vulnerable patient demographics, including those with chronic conditions or undergoing intensive medical treatments.
Frequently Asked Questions
What is SER-155?
SER-155 is an investigational oral live biotherapeutic designed to improve immune function and reduce the risk of infections in patients undergoing allo-HSCT.
What were the findings presented at ASCO?
The findings indicated significant improvements in immune reconstitution markers such as IL-7 levels and CD4+ T-cell frequency, suggesting enhanced immune recovery.
When can we expect the Phase 2 trial for SER-155?
Seres Therapeutics plans to submit the Phase 2 trial protocol to the FDA shortly, aiming to continue research and development.
Why is SER-155 important for allo-HSCT patients?
Allo-HSCT patients are at high risk for infections, and SER-155 may improve immune recovery crucial for their long-term health and outcomes.
What distinguishes Seres Therapeutics in the biotech industry?
Seres has a strong focus on live biotherapeutics and innovative microbiome therapies, positioning it as a leader in addressing unmet medical needs in vulnerable populations.
